Ultra-Deep Sequencing Validates Safety of CRISPR/Cas9 Genome Editing in Human Hematopoietic Stem and Progenitor Cells

In three separate primary human hematopoietic stem and progenitor cell donors assessed in technical triplicates, researchers electroporated high-fidelity Cas9 protein targeted to three loci and harvested genomic DNA at days four and ten.